=====================  Product Identification  =====================

MSDS NAME:TESLAC TABLETS, 50 MG
Status Code:A
MSDS Number: CLFKQ
=== Responsible Party ===
Company:E R SQUIBB MEDATOPE DIV
Address:5 GORDIS RD  BLDG 124
Box:191
City:NEW BRUNSWICK
State:NJ
ZIP:08903
Country:US
Info Phone Num:609-921-4081
Emergency Phone Num:609-921-4081
CAGE:4T649
=== Contractor Identification ===
Company:E R SQUIBB MEDATOPE DIV
Address:5 GORDIS RD  BLDG 124
Box:191
City:NEW BRUNSWICK
State:NJ
ZIP:08903
Country:US
Phone:609-921-4081
CAGE:4T649

=============  Composition/Information on Ingredients  =============

Name:TESTOLACTONE
CAS:968-93-4
= Wt:18.5

Name:LACTOSE
CAS:63-42-3
RTECS #:OD9625000
> Wt:1.

Name:CORN STARCH
CAS:9005-25-8
RTECS #:GM5090000
> Wt:1.
OSHA PEL:15 MG/M3
ACGIH TLV:10 MG/M3

Name:CALCIUM STEARATE
CAS:1592-23-0
RTECS #:WI3000000
< Wt:1.

Name:GELATIN
< Wt:1.

=====================  Hazards Identification  =====================

Routes of Entry: Inhalation:YES  Skin:YES  Ingestion:YES
Reports of Carcinogenicity:NTP:NO    IARC:NO	OSHA:NO
Health Hazards Acute and Chronic:ACUTE:INGESTION:TESTOLACTONE IS
    MODERATELY TOXIC AFTER ACUTE INGESTION.ACUTE EXPOSURE MAY CAUSE
    NAUSEA,VOMITING,AND DIARRHEA.INHALATION:IF TABLETS ARE CRUSHED, IF
    THE RESULTING MATERIAL IS INHALED IN  SUFFICIENT
    QUANTITY,RESPIRATORY IRRITATION MAY OCCUR.EYE:IF TESLAC TABLETS ARE
    CRUSHED,AND MATERIAL CONTACTS THE EYE,IT MAY CAUSE
    IRRITATION.CHRONIC:TESLAC TABLETS ARE INTENDED FOR ORAL USE UNDER
    THE  SUPERVISION OF PHYSICIANS EXPERIENCED IN CANCER
    CHEMOTHERAPY.ADVERSE EFFECTS ASSOCIATED WITH REPEATED SYSTEMIC
    EXPOSURE TO THERAPEUTIC DOSES OF TESTOLACTONE MAY INCLUDE:FACIAL
    RASH AND INCREASED BLOOD  PRESSURE.
Explanation of Carcinogenicity:TARGET ORGANS: POSSIBLY THE PITUITARY
    GLAND, AND MALE AND FEMALE REPRODUCTIVE ORGANS.
Effects of Overexposure:SEE HEALTH HAZARD SECTION.
Medical Cond Aggravated by Exposure:THERAPEUTIC DOSES OF THIS MATERIAL
    MAY AGGRAVATE HYPERCALCEMIA.TESTOLACTONE IS NOT RECOMMENDED FOR
    THERAPEUTIC USE DURING PREGNANCY SINCE SAFE USE OF THE DRUG HASN'T
    BEEN DEMONSTRATED

=======================  First Aid Measures  =======================

First Aid:INGESTION: VOMITING MAY BE INDUCED IF PERSON IS CONSCIOUS AND
    NOT EXPERIENCING CONVULSIONS. NEVER GIVE ANYTHING BY MOUTH TO AN
    UNCONSCIOUS PERSON.  INHALATION: REMOVE EXPOSED PERSON TO FRESH
    AIR.  IF  PERSON IS NOT BREATHING GIVE ARTIFICIAL RESPIRATION.  IF
    BREATHING IS DIFFICULT ADMINISTER OXYGEN.  SKIN: WASH THOROUGHLY
    WITH SOAP AND WATER.  EYE: HOLD EYELIDS APART AND FLUSH WITH PLENTY
    OF WATER F OR 15 MINUTES.  IN ALL CASES, SEEK MEDICAL ATTENTION.

=====================  Fire Fighting Measures  =====================

Lower Limits:N/D
Upper Limits:N/D
Extinguishing Media:IN CASE OF FIRE USE WATER, CARBON DIOXIDE, FOAM OR
    DRY CHEMICAL.
Fire Fighting Procedures:FIREFIGHTERS SHOULD WEAR SELF-CONTAINED
    BREATHING APPARATUS, FLAME AND CHEMICAL RESISTANT CLOTHING, BOOTS
    AND GLOVES.  EVACUATE PERSONNEL TO UPWIND DIRECTION, REMOVE
    UNNEEDED MATERIAL AND COOL CONTAIN ER WITH WATER FROM A MAXIMUM
    DISTANCE.
Unusual Fire/Explosion Hazard:NONE KNOWN.

==================  Accidental Release Measures  ==================

Spill Release Procedures:SCOOP UP TABLETS AND PLACE IN SUITABLE
    CONTAINER.	IF TABLETS ARE CRUSHED, CLEAN POWDER WITH DAMP CLOTH OR
    TOWELS.  TREAT PRODUCTS AND CONTAMINATED MATERIALS AS IF THEY WERE
    HAZARDOUS WASTE.  INCINERA TION IS RECOMMENDED.

======================	Handling and Storage  ======================

Handling and Storage Precautions:AVOID INHALATION, SKIN OR EYE CONTACT
    WITH CRUSHED OR BROKEN TABLETS.  STORE IN TIGHT CONTAINERS AT 15-30
    DEGREES C; EXPOSURE TO EXCESSIVE HEAT SHOULD BE AVOIDED.

=============  Exposure Controls/Personal Protection  =============

Respiratory Protection:NIOSH APPROVED RESPIRATORS WITH HEPA FILTERS ARE
    RECOMMENDED WHEN HANDLING LARGE QUANTITIES OF BROKEN OR CRUSHED
    TABLETS IN THE ABSENCE OF SUITABLE EXHAUST VENTILATION.
Ventilation:LOCAL EXHAUST RECOMMENDED WHEN HANDLING QUANTITIES OF
    BROKEN OR CRUSHED TABLETS.
Protective Gloves:WEAR LATEX SURGICAL GLOVES WHEN HANDLING QUANTITIES
    OF BROKEN OR CRUSHED TABLET
Eye Protection:WEAR SAFETY GLASSES
Other Protective Equipment:WEAR COVERALLS WHEN THE POTENTIAL FOR SEVERE
    DUSTY CONDITIONS EXISTS.
Work Hygienic Practices:WASH HANDS AFTER HANDLING COMPOUND AND BEFORE
    EATING, SMOKING, USING LAVATORY, AND AT END OF DAY.
Supplemental Safety and Health
NOTE TO PHYSICIANS: TESLAC TABLETS CONTAIN TESTOLACTONE, A SYNTHETIC
    ANTINEOPLASTIC AGENT AND ANABOLIC AGENT.  TESTOLACTONE IS A
    POSSIBLE TERATOGEN AND A POSSIBLE REPRODUCTIVE TOXIN.

==================  Physical/Chemical Properties  ==================

Vapor Density:N/D
Spec Gravity:N/D

=================  Stability and Reactivity Data  =================

Stability Indicator/Materials to Avoid:YES
NONE KNOWN.
Hazardous Decomposition Products:CO, CO2

===================  Toxicological Information	===================

Toxicological Information:ACUTE: LD50: ACUTE ORAL LD50 (MOUSE)=1,630
    MG/KG; ACUTE ORAL LD50 (DOG)=593 TO 926 MG/KG; ACUTE IP LD50
    (MOUSE)=160 MG/KG	  REPRODUCTIVE EFFECTS: IN ANIMAL STUDIES
    TESTOLACTONE PRODUCED ANABOLIC EFF ECTS.  IT IS NOT KNOWN WHETHER
    TESTOLACTONE IS DISTRIBUTED INTO MILK.

=====================  Ecological Information  =====================

Ecological:NO INFORMATION.

====================  Disposal Considerations  ====================

Waste Disposal Methods:DISPOSE OF IN ACCORDANCE WITH NATIONAL, STATE,
    LOCAL AND APPLICABLE COUNTRY REGULATIONS.  TREAT PRODUCT AND
    CONTAMINATED MATERIALS AS HAZARDOUS WASTE.	INCINERATION AT AN
    APPROVED FACILITY IS RECOMMEN DED.

=====================  Regulatory Information  =====================

Federal Regulatory Information:U.S. FEDERAL : TESTOLACTONE IS SUBJECT
    TO THE FEDERAL CONTROLLED SUBSTANCES ACT OF 1970 AS AMMENDED BY THE
    ANABOLIC STEROIDS CONTROL ACT OF 1990, AS A SCHEDULE III (C-III)
    DRUG.

=======================  Other Information  =======================

 Disclaimer (provided with this information by the compiling agencies):
 This information is formulated for use by elements of the Department
 of Defense.  The United States of America in no manner whatsoever,
 expressly or implied, warrants this information to be accurate and
 disclaims all liability for its use.  Any person utilizing this
 document should seek competent professional advice to verify and
 assume responsibility for the suitability of this information to their
 particular situation.

*** END OF RECORD ***